NCT05691621 is a clinical trial of Standard Reagents, Whole Blood in Acute Kidney Injury, sponsored by Fengyun Wang.

Who is sponsoring NCT05691621?

NCT05691621 is sponsored by Fengyun Wang.

What drugs are being tested in NCT05691621?

Interventions in NCT05691621: Standard Reagents, Whole Blood.

What condition does NCT05691621 study?

NCT05691621 studies Acute Kidney Injury, Sepsis.

Is NCT05691621 still recruiting?

NCT05691621 is currently status unknown. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT05691621

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Galectin-3 in Septic and Non-septic Acute Kidney Injury

Status unknown Last updated 20 January 2023

What this trial tests

trial testing Standard Reagents, Whole Blood in Acute Kidney Injury in 150 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Fengyun Wang
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 January 2023
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across China

Drugs / interventions tested

Standard Reagents, Whole Blood — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sepsis — all drugs for Sepsis →

Sponsor

Fengyun Wang — full company profile →

Who can join

Adults 18 to 85, any sex, with Acute Kidney Injury or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute kidney injury (AKI) is a common critical condition with high morbidity and mortality. The level of circulating Galectin-3 (Gal3) largely depends on renal function, so it is elevated in patients with AKI or CKD; elevated Gal3 also aggravates the progression of CKD after the onset of AKI. The proinflammatory and profibrotic properties of Gal3 may render it to be one of the key molecules mediating AKI, CKD, and cardiorenal syndrome. In this prospective observational study, the investigators will explore the differences of Gal3 levels among septic AKI, non-septic AKI, and non-AKI patients and its correlation with prognosis, inflammation, and disease severity in the ICU.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05691621 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fengyun Wang
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05691621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing